San Mateo County Rabid Bat Alert - Learn About Exposure Risks and Rabies Safety Steps.

Protect Yourself and Your Pets Against the Deadly Rabies Virus1

Rabies is a viral disease passed from one species to the next—usually through a bite from a rabid animal. Rabies causes severe swelling of the brain. Any mammal can get it, including you, your dog, or cat. Unless you take immediate steps to get protected, rabies is almost always fatal.1-5

A medical professional discussing treatment for rabies exposure
Close up rendering of the rabies virus

Learn to Avoid One of the World’s Deadliest Infectious Diseases

Rabies Watch is your online source for information about rabies. There is no cure for rabies, but rabies can be prevented. With the right information, you can know what to look for, how to protect yourself, and what to do if you have been exposed to rabies.

View data from the World Health Organization about the number of human deaths from rabies in the United States.

What Is Rabies?

Rabies is a deadly disease caused by a virus that can be found in the saliva of a rabid animal. The most common way for the disease to move from one mammal to another is through a bite wound. Once saliva gets under the skin, the virus moves to the spinal cord and brain, causing an acute swelling called encephalitis.6

After a person (or an animal) starts showing symptoms, the disease is almost always fatal. The best you can do is prevent it from spreading and infecting your body.3

Menacing looking bat in flight

Wild Animals With Rabies in the US

Wild animals pose the biggest risk for transmitting rabies to humans in the US. This is especially true for bats. Every year in the US, an estimated 100,000 people receive treatment to prevent rabies, mostly because they have had a bite or other physical encounter with an animal.1,7,8

See how many cases of rabid animals there have been in your state.

Closeup of a human hand with bleeding wounds inflicted by an animal that may have rabies

What Do I Do if I Think I Have Been Exposed to Rabies?

If you’ve had a physical encounter with any of the top rabies carriers in the US—raccoon, skunk, fox, or bat—there are some important things you need to do now.

Learn about the 5 steps to take after you’ve been bitten, scratched, or wounded by a wild or stray animal.

What Is the Treatment for Rabies Exposures?

Okay, you suspect you may have been exposed to rabies. You’ve followed the 5 steps. You got yourself to your local hospital’s emergency room. Here are the 3 things your doctor will do.

On a hiking trial, a father and his children look at a guidebook that references rabies information

Rabies: Myth or Fact?

Rabies has been eradicated in the US

Important Safety Information for HyperRAB® (rabies immune globulin [human])

View Close

Indication and Usage
HYPERRAB® (rabies immune globulin [human]) is indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies.

Limitations of Use
Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. For unvaccinated persons, the combination of HYPERRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis. Beyond 7 days (after the first vaccine dose), HYPERRAB is not indicated since an antibody response to vaccine is presumed to have occurred.

Important Safety Information

For infiltration and intramuscular use only.

Severe hypersensitivity reactions may occur with HYPERRAB. Patients with a history of prior systemic allergic reactions to human immunoglobulin preparations are at a greater risk of developing severe hypersensitivity and anaphylactic reactions. Have epinephrine available for treatment of acute allergic symptoms, should they occur.

HYPERRAB is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common adverse reactions in >5% of subjects during clinical trials were injection-site pain, headache, injection-site nodule, abdominal pain, diarrhea, flatulence, nasal congestion, and oropharyngeal pain.

Do not administer repeated doses of HYPERRAB once vaccine treatment has been initiated as this could prevent the full expression of active immunity expected from the rabies vaccine.

Other antibodies in the HYPERRAB preparation may interfere with the response to live vaccines such as measles, mumps, polio, or rubella. Defer immunization with live vaccines for 4 months after HYPERRAB administration.

Please see full Prescribing Information for HYPERRAB.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Indication and Usage
HYPERRAB® (rabies immune globulin [human]) is indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies.

Limitations of Use
Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. For unvaccinated persons, the combination of HYPERRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis. Beyond 7 days (after the first vaccine dose), HYPERRAB is not indicated since an antibody response to vaccine is presumed to have occurred.

Important Safety Information

For infiltration and intramuscular use only.

Severe hypersensitivity reactions may occur with HYPERRAB. Patients with a history of prior systemic allergic reactions to human immunoglobulin preparations are at a greater risk of developing severe hypersensitivity and anaphylactic reactions. Have epinephrine available for treatment of acute allergic symptoms, should they occur.

HYPERRAB is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common adverse reactions in >5% of subjects during clinical trials were injection-site pain, headache, injection-site nodule, abdominal pain, diarrhea, flatulence, nasal congestion, and oropharyngeal pain.

Do not administer repeated doses of HYPERRAB once vaccine treatment has been initiated as this could prevent the full expression of active immunity expected from the rabies vaccine.

Other antibodies in the HYPERRAB preparation may interfere with the response to live vaccines such as measles, mumps, polio, or rubella. Defer immunization with live vaccines for 4 months after HYPERRAB administration.

Please see full Prescribing Information for HYPERRAB.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Important Safety Information for HyperRAB® (rabies immune globulin [human])

Indication and Usage
HYPERRAB® (rabies immune globulin [human]) is indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies.

Limitations of Use
Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. For unvaccinated persons, the combination of HYPERRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis. Beyond 7 days (after the first vaccine dose), HYPERRAB is not indicated since an antibody response to vaccine is presumed to have occurred.

Important Safety Information

For infiltration and intramuscular use only.

Severe hypersensitivity reactions may occur with HYPERRAB. Patients with a history of prior systemic allergic reactions to human immunoglobulin preparations are at a greater risk of developing severe hypersensitivity and anaphylactic reactions. Have epinephrine available for treatment of acute allergic symptoms, should they occur.

HYPERRAB is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common adverse reactions in >5% of subjects during clinical trials were injection-site pain, headache, injection-site nodule, abdominal pain, diarrhea, flatulence, nasal congestion, and oropharyngeal pain.

Do not administer repeated doses of HYPERRAB once vaccine treatment has been initiated as this could prevent the full expression of active immunity expected from the rabies vaccine.

Other antibodies in the HYPERRAB preparation may interfere with the response to live vaccines such as measles, mumps, polio, or rubella. Defer immunization with live vaccines for 4 months after HYPERRAB administration.

Please see full Prescribing Information for HYPERRAB.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

References

  1. Centers for Disease Control and Prevention (CDC). About rabies. Updated January 27, 2026. Accessed August 10, 2026. https://www.cdc.gov/rabies/about/.
  2. Rao AK, Briggs D, Moore SM, et al. Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies: recommendations of the advisory committee on immunization practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(18):619-627.
  3. Khan B, Shrivastava N, Sheikh NP, Singh PK, Jha HC, Parmar HS. Rabies vaccines: journey from classical to modern era. Veterinary Vaccine. 2025;4(1):100105.
  4. American Veterinary Medical Association. Rabies. Updated 2026. Accessed August 11, 2026. https://www.avma.org/resources-tools/avma-policies/rabies.
  5. Lyabangi JF, Mahulu EM, Sandetwa J, John WA, Madoshi PB. Exploring global strategies to combat rabies: addressing limitations and enhancing effectiveness. Vet Med Sci. 2025;11(6):e70669.
  6. Manjunatha KG, Chandrahasa C, Akshay SD, et al. Comprehensive update on rabies: a neglected zoonotic disease of public health concern. Prog Microbes Mol Biol. 2023;6(1):a0000385.
  7. Centers for Disease Control and Prevention (CDC). Rabies in the United States: protecting public health. Updated September 30, 2025. Accessed August 11, 2026. https://www.cdc.gov/rabies/php/protecting-public-health/index.html.
  8. Boutelle C, Bonaparte S, Orciari LA, et al. Rabies surveillance in the United States during 2023. J Am Vet Med Assoc. 2025;263(10):1310-1317.